Fig. 1.

TAK-003 elicits a potent and durable DENV-specific cellular immune response following vaccination. PBMCs from individuals immunized with TAK-003 were assessed for markers of T cell activation by flow cytometry on days 0, 14, 28, and 120 post-vaccination. a Representative plots demonstrating CD8⁺ T cell activation as assessed by CD38 and HLA-DR upregulation on days 0, 14, 28, and 120 post-vaccination. b Aggregate analysis from 55 TAK-003 recipients, demonstrating maximal CD8⁺ T cell activation on day 28 post-vaccination, returning to baseline by day 120. c Representative plots demonstrating CD4⁺ T cell activation as assessed by CD38 and HLA-DR upregulation on days 0, 14, 28, and 120 post-vaccination. d Aggregate analysis from 55 TAK-003 recipients, demonstrating maximal CD4⁺ T cell activation on day 14 post-vaccination, returning to baseline by day 120. e Representative plots demonstrating DENV-specific IFN-γ production and CD8 T cell degranulation (as assessed by surface CD107a expression) days 0, 14, 28 and 120 post-vaccination. f Aggregate analysis from 12 TAK-003 recipients. Cytokine production was assessed following stimulation with peptide pools demonstrated by ELISPOT analysis as being immunogenic at day 120 post vaccination in each individual. *P < 0.05, **P < 0.01, ****P < 0.0001 (Paired two-tailed t-test); ns, not significant. Source data are provided as a Source Data file